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Background: The composition of the intestinal microbiota seems to be an important factor in determining the
clinical outcome in children with short bowel syndrome (SBS). Alterations in the microbiota may result in serious
complications such as small bowel bacterial overgrowth (SBBO) and intestinal mucosal inflammation that lead to
prolonged parenteral nutrition (PN) dependency with subsequently increased risk of liver failure and sepsis. To date,
there are no reported mappings of the intestinal microbiome in children with SBS. Here, we present the first report
on the intestinal microbial community profile in children with SBS.
Findings: The study includes children diagnosed with SBS in the neonatal period. Healthy siblings served as
controls. Fecal samples were collected, and microbial profiles were analyzed by using 16S rRNA gene sequencing
on the Illumina MiSeq platform. We observed a pronounced microbial dysbiosis in children with SBS on PN
treatment with an increased and totally dominating relative abundance of Enterobacteriacae in four out of five
children compared to children with SBS weaned from PN and healthy siblings.
Conclusions: The overall decreased bacterial diversity in children with SBS is consistent with intestinal microbiome
mappings in inflammatory bowel diseases such as Crohn’s disease and necrotizing enterocolitis in preterm infants.
Our findings indicate that intestinal dysbiosis in children with SBS is associated with prolonged PN dependency.
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Background
Pediatric intestinal failure (IF) has been defined as the
inability of the gastrointestinal tract to sustain adequate
growth, hydration, and electrolyte homeostasis in chil-
dren without parenteral nutrition (PN). Short bowel syn-
drome (SBS) is the most common cause of pediatric IF.
The condition is caused by massive small bowel resec-
tions due to necrotizing enterocolitis (NEC) or volvulus
and congenital malformations such as gastroschisis and
jejunal atresia. Neonatal SBS is a disease with a high
morbidity and mortality [1]. The medical management
of SBS aims to establish full enteral/oral feedings and
weaning from PN.
The intestinal microbiota seems to be a major factor
in determining the successful clinical outcome in SBS
defined as independence of PN treatment and intestinal* Correspondence: helene.lilja@kbh.uu.se
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article, unless otherwise stated.adaptation. Alterations in the microbiota can result in
serious complications such as small bowel bacterial over-
growth (SBBO) and intestinal mucosal inflammation that
may prevent weaning from PN by compromising intes-
tinal absorptive functions [2,3]. Luminal/oral antibiotic
long-term treatment has been recommended for SBBO
in children [4,5]. Most cases of SBS occur in neonates
during a period when the sterile intestines normally are
colonized by bacteria, reaching a microbial profile charac-
teristic of the adult gastrointestinal tract around 2 to 4 years
of age [6]. A disruption in the balanced intestinal microbial
community, that is, dysbiosis, with an increased relative
abundance of facultative anaerobic Enterobacteriaceae in
the large bowel is seen in inflammatory bowel disease
(IBD) in mouse models, in humans with Crohn’s disease,
and in NEC in preterm infants [7,8].
To date, there are no reported mappings of the
intestinal microbiota in children with SBS. Here, we
present the first report on the microbial profile in chil-
dren with SBS by using 16S rRNA gene sequencing on
the Illumina MiSeq platform.Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Patients
This study was approved by the regional committee
on medical research ethics in Uppsala (Dnr2012/002).
Informed written consent for sample collection and subse-
quent analyses was obtained from the parents. Characte-
ristics of the study group and corresponding healthy
siblings are demonstrated in Table 1. The study includes
11 children between the age of 1.5 to 7 years diagnosed
with IF/SBS in the neonatal period, of whom two are from
a set of triplets (2A and 3A) (Table 1). All children except
one were prematurely born. Child 1A, 8A, and 13A
underwent bowel lengthening procedure with serial trans-
verse enteroplasty (STEP) [9]. Five children were not
weaned from PN at the time of the study. Seven healthy
siblings served as controls. Children on PN had an oral
and/or enteral intake of lactose-free hydrolysed protein
formula and an age-appropriate intake of solid foods with
reduction in disaccharide content according to Table 1.
Data collection and statistical analysis
Fecal samples were collected and stored at −80°C until
analysis. DNA was extracted from each fecal sample
with ultra-clean fecal DNA isolation kit (MoBio, Naxo
Ltd, Tartu, Estonia) according to the manufacturer’s
instructions.Table 1 Characteristics of the study group and corresponding
Child GA Age (year) Diagnosis Remaining small
bowel length (cm)
1Aa 35 4 Jejunal atresia 20 jejunum
3Aa,b 23 3 NEC 10 jejunum
8Aa 33 4 Gastroschisis 15 jejunum
9Aa 25 4 NEC 10 jejunum
12A 41 1.5 Volvulus 27 jejunum
2Ab 23 3 NEC All, (only 2 cm resection)
4A 23 2.5 NEC 30 jejunum + 5 ileum
11A 24 3 NEC 5 jejunum + 17 ileum
13A 34 7 Jejunal atresia 35 jejunum
16A 24 6 Volvulus 45 jejunum + 25 ileum
18A 26 4 NEC 10 jejunum + 20 ileum








a = SBBO, b = triplets, GA = gestational age.Sequencing libraries were prepared by amplifying the
V3-V4 region of the 16S rRNA gene using the 341f-805r
primers, described by Hugerth et al. [10]. After the ini-
tial amplification, a second PCR was performed to attach
Illumina adapters as well as barcodes that allows for
multiplexing. Samples were sequenced using the Illumi-
naMiSeq, producing in total 10,136,440 2 × 300 base pair
reads with an average of 307,165 reads per sample.
Primer sequences were trimmed away, and the paired-
end reads produced by the sequencing instrument were
merged using SeqPrep version 1.1 (https://github.com/
jstjohn/SeqPrep) with default parameters and thereafter
processed with the QIIME 1.8.0 pipeline (Quantitative
Insight into Microbial Ecology) [11]. Merged reads were
randomly subsampled to an even depth of 151,610 reads
per sample, which was the minimum number of reads
among the samples. Using the UCLUST [12] algorithm
built into the QIIME pipeline, sequences were clustered at
97% identity against the Greengenes reference database
producing 4,216 OTUs (operational taxonomic units)
[11]. For each sample; number of non-singleton OTU as
well as most dominant OTU, with respective description,
is presented in the supplemental data (Additional file 1).
Shannon indexes for diversity were calculated for SBS
children on and off PN and tested for significance with
Wilcoxon rank-sum test. Using the QIIME pipeline,healthy siblings
Remaining ICV Remaining
colon length




No 1/3 75% 0.104
No 1/2 70% 3.29
No 1/2 30% 0.099
No 1/2 80% 1.63
No 1/2 50% 1.16
Yes All Off PN 4.67
Yes All Off PN 4.21
Yes All Off PN 4.30
No 1/2 Off PN 3.36
No 2/3 Off PN 3.38
Yes Yes Off PN 3.17
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for investigation of beta diversity through plotting PCA
coordinates. Details on 16S rRNA gene primers, amplifica-
tion conditions, and sample barcodes are shown in sup-
plemental data (Additional file 2).
Results
Figure 1 shows that Shannon diversity index is signifi-
cantly reduced in children with SBS still on PN com-
pared to children weaned from PN. None of the children
on PN had remaining ICV.
In children still on PN, four out of five (1A, 3A, 8A,
and 9A) were examined for several episodes of suspected
SBBO, also at the time of fecal sampling (Table 1). They
were treated with oral metronidazole, trimethoprim-
sulfamethoxazole, gentamicin, or amoxicillin-clavulanic
acid. In these patients, Enterobacteriacae was the most
relative abundant taxonomic family and totally dominated
the microbial community in these children (Figure 2). The
remaining patient in this group (12A), still on PN and
with a reduced Shannon diversity index, showed a relative
abundant dominance of Lactobacillaceae followed by
Enterobacteriacae. Altogether, a high relative abundanceFigure 1 Shannon diversity index in children with SBS still on PN
compared to children weaned from PN.of Enterobacteriacae was associated with SBS in 6 out of
11 patients (1A, 3A, 8A, 9A, 11A, and 12A). In the
remaining five SBS patients, all off PN (2A, 4A, 13A, 16A,
and 18A), there was a more diverse microbiota com-
position and a more uniform distribution of taxonomic
families. However, none except one (2A) of the SBS chil-
dren reached Shannon diversity indexes at the same levels
as the controls (Table 1). In one of the children still on PN
(1A), upper and lower endoscopy with biopsies revealed
macroscopic and histopathologic acute inflammation in
the stomach, duodenum, small bowel, and proximal colon.
In child 3A, also on PN, upper endoscopy with biopsies
demonstrated small bowel villous atrophy.
In Figure 3, the Shannon diversity indexes and, in
Figure 4, the unweighted UniFrac distances in children
with SBS on PN (1A, 3A, 8A, 9A, 12A), SBS children
weaned from PN (2A, 4A, 11A, 13A, 16A, 18A), and
siblings (2C1, 2C2, 11C1, 11C2, 12C, 13C1, 13C2) are
compared.
We had the unique opportunity to study triplets repre-
senting all three groups. Child 2A and child 3A were
male triplets born at 23 weeks of gestation. Both boys
suffered from NEC in the neonatal period resulting in
small bowel resections (Table 1). The third triplet boy
(2C2) remained healthy. In child 2A, only 2 cm of the
small bowel was resected, however he developed IF after
extensive NEC and became dependent on PN. During
PN treatment, he had no signs of SBBO. He was weaned
to full oral feeding and without antibiotics 3 months be-
fore the time of fecal sampling. His intestinal bacterial
diversity was similar to his healthy brother (SDI 4, 67
and 4, 97, respectively).
Child 12A was treated with antibiotics only during the
first 2 weeks postnatally, had no signs of SBBO, and
weaning from PN advanced but slowly. Her fecal bac-
terial diversity showed Lactobacillacae as the most rela-
tive abundant taxonomic family in accordance to our
previous findings (Figure 2) [13]. We could detect Clos-
tridium difficile in two out of ten SBS patients (patient
2A and 11A) and in very low relative abundance (data
not shown).
Conclusions
The tendency for SBBO and bowel inflammation to
delay or prevent weaning from PN in these children with
SBS seems to be related to microbial dysbiosis in the
intestinal tract. This finding is in accordance with a
previous study demonstrating that PN administration
was independently associated with SBBO [14]. Influence
of PN on the change in profile due to starvation of the
microbiome is unlikely since malabsorption of oral/
enteral nutrition is the major problem in SBS. In general,
the observed changes in the microbiota in SBS children
are most likely both at cause and a consequence of the
Figure 2 Microbial communities in children with SBS on PN (1A, 3A, 8A, 9A, 12A), SBS children weaned from PN (2A, 4A, 11A, 13A, 16A, 18A), and
siblings (2C1, 2C2, 11C1, 11C2, 12C, 13C1, 13C2). The figure is showing the relative abundance of the 19 most common taxonomic families that
accounts for at least 84% of the abundance in all samples.
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the small study group, and confounding factors that might
influence the results are age, intestinal length, and anti-
biotic treatment. However, the cohort in the present study
represents children with SBS in the clinical practice.Figure 3 Shannon diversity index in children with SBS on PN (1A, 3A, 8A, 9
and siblings (2C1, 2C2, 11C1, 11C2, 12C, 13C1, 13C2).In our center, we treat SBBO with oral antibiotics as rec-
ommended by other centers [4-6]. However, it is most
likely that antibiotics will further contribute to dysbiosis in
these children. In children with SBS, normal colonization
is disrupted due to early and frequent antibiotic use andA, 12A), SBS children weaned from PN (2A, 4A, 11A, 13A, 16A, 18A),
Figure 4 PCoA plot describing unweighted UniFrac distance between samples. Pairwise distances between all samples are projected onto a
two-dimensional space where the axis PC1 describes the highest degree of variation. Samples that are clustered closely together are thus considered
to share a larger proportion of the phylogenetic tree in comparison to samples that are more separated.
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bacteria to expand. Antibiotics have been suggested to
lower colonization resistance against Enterobacteriacae
such as Escherichia coli and Salmonella enterica, by in-
creasing the inflammatory tone of the intestinal mucosa
[15]. Most frequently, probiotics are used to modify the in-
testinal microbiota in SBS; however, there are conflicting
findings and reports of probiotic-associated septicemia [16].
The overall decreased bacterial diversity in our chil-
dren with SBS is consistent with intestinal dysbiosis in
IBD patients, infants with NEC, and has also been de-
scribed in a piglet model of SBS [7,8,17,18]. In addition,
children with recurrent C. difficile-associated diarrhea
show a decreased fecal diversity with a reduction of
Bacteriodetes and Firmicutes [19]. In these children, fecal
microbiota transplantation (FMT) has a success rate
greater than 90%. Such treatment has also been success-
fully used as a complement to treat IBD [19,20]. Conse-
quently, FMT could prove to be a treatment alternative
in carefully selected cases of SBS with dysbiosis. How-
ever, since children with SBS often are vulnerable due to
their initial health status, the difficulties and risks of
FMT must be considered. Although the incidence of
severe side-effects is rare, one such risk is contracting
illness from the donor where asymptomatic microorga-
nisms that cause no problems in a healthy donor may
cause a reaction in the recipient. In addition, mass
arrival of a new microbiota may also trigger autoimmune
illness as well as bacteria and septic shock. Extra care
should also be taken with FMT if the patient has any
sign of immunodeficiency [21].This is the first report describing the intestinal micro-
bial profile in children with SBS using next-generation
sequencing. We observed a pronounced microbial dys-
biosis in children with SBS still on PN compared to
children weaned from PN with an increased relative
abundance of proteobacteria, most of whom has been
long-term treated with antibiotics. Our findings indicate
that intestinal dysbiosis in children with SBS is asso-
ciated with impaired outcome with prolonged PN de-
pendency. Future studies need to find out new strategies
to treat intestinal dysbiosis in these children.Availability of supporting data
The data sets supporting the results of this report are in-
cluded within the article (and its additional file). The se-
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of 16S rRNA gene primers, amplification conditions and sample
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